Navigation Links
Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
Date:2/7/2008

EMERYVILLE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its second quarter 2008 financial results, for the quarter ended December 31, 2007, on February 11. The Company will host a conference call to discuss the earnings and to give a corporate update.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Craig W. Carlson, Vice President and Chief Financial Officer. The details for the call are as follows:

Live Call:

-- Date: Monday, February 11, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-857-6147 (U.S.) 719-325-4822 (International)

Webcast of Call:

-- A live webcast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

The call will be archived and accessible at the same website for 90 days

Telephonic Replay:

A playback of the conference call will be available from 10:00 AM PT

February 11th through midnight February 15, 2008.

Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820

(international). Replay access code: 3898964.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications
2. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
3. Neurobiological Technologies Sets Date for Second Quarter Financial Results
4. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
7. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
8. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
9. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
10. Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions
11. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personaliz...to take place on February 22-24, 2010 in Philadelp...nce we will highlight key issues in forming partne... experiences. , Minneapol...Arrowhead’s 2010 Personalized Medicine Part...
(Date:11/5/2009)... Nov. 5 The endangered black-foote... U.S. This rare carnivore feeds on prairie dogs. ...and often entire population die-offs in towns occu... implemented a ferret breeding program and has bee...rmerly native habitat. Unfortunately, plague can ...
(Date:11/5/2009)...lif., Nov. 5 ThermoGenes...nnovative products for processing and storing adul... quarter of fiscal 2010. ,, For the quarter end...es of $5.2 million, a 15 percent increase over rev...ago. The Company said the key contributors to the ...
(Date:11/5/2009)...v. 5 BioSpecifics Techno... company developing first-in-class collagenase-bas... for the third quarter ended September 30, 2009. ...of this year, the FDA,s Arthritis Advisory Committ... approval of XIAFLEX(TM) for the treatment of Dupu...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
... Biotech Products, L. P. Supports Program to Recog...o recognize the,extraordinary commitment of oncolo...ounced its support of CURE magazine,s 2008 Extraor...nors one of the thousands of,exceptional oncology ...cation, compassion and helpfulness. Last year, mor...
...ands the Company,s Clinical Stage Product Portfoli...uticals,Inc. today announced that it is has comple...and commercialize products under AstraZeneca,s IP ...tors (AI) in combination with,estrogen and progest...Meditrina,s clinical stage product portfolio which...
...ERSBURG, Md., Feb. 6 Iomai Corporation,(Nasdaq: ...ompany,s,president and chief executive officer, wi...onference in New York City on Tuesday, Feb. 12. Mr... Time in the in New Amsterdam,Suite of the Waldorf...ate and clinical milestones and,detail the results...
Other Biology Technology:Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 3Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
(Date:11/9/2009)...-- Genencor, a division of Danisco, has won the na...n Institute of Chemical Engineers (AIChE) for its ... ethanol. Yesterday, Robert Davis, Chair of the AI...n Steele, who is Marketing Director, Biomass Enzym...n Kelley, who is Senior Engineer, Biomass Applicat...
(Date:11/8/2009)...rdue University have discovered a new approach for...uries using nano-spheres that could be injected in...nthetic "copolymer micelles" are drug-delivery sph...00 times smaller than the diameter of a red blood ...liver drugs for cancer treatment and other therapi...
(Date:11/6/2009)...y with their arboreal hosts. But new research sugg...s of choice, the ants can get destructive to neigh...ovember issue of the American Naturalist , is the... and it reopens a centuries-old debate on the rela...tain species of plants and trees have cozy relatio...
Breaking Biology News(10 mins):Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 1Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 1Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 3Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 1Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 2
...The legacy of nuclear weapons and nuclear energy d...ozens of sites across the United States and many m...e uranium is transported through ground water as u...um immobilization in contaminated ground water and...ic molecules known as electron donors to stimulate...
...in the UK and funded by the UK Biotechnology and B... a new drug discovery tool to identify a new playe...nding could spark a completely new class of drugs ...is week in Nature Chemical Biology researchers a...askatchewan graduate Dr Grant Churchill, explain h...
...ed an algorithm that meshes existing data to produ...respond to stimuli. Using this new method, Whitehe...logy scientists have analyzed alpha-synuclein toxi...t cell survival. Misfolded copies of the alpha-syn...rkinson,s disease. , RELEVANCE: Until now, data o...
Other Biology News:Patience pays off with methanol for uranium bioremediation 2Canadian scientist mines drugs database for new diabetes treatment 2Calculating gene and protein connections in a Parkinson's disease model 2Calculating gene and protein connections in a Parkinson's disease model 3Calculating gene and protein connections in a Parkinson's disease model 4
Mouse Anti-20S Proteasome alpha1, 2, 3, 5, 6, & 7-Subunits Monoclonal Antibody, Unconjugated, Clone MCP231 from Calbiochem
...een the 500 l and 4 ml centrifugal concentrators. ...spin products with low internal surface and membra...olutions. ,Available with a choice of PES, Cell...highest flexibility for process optimisation. ,A...
Mouse Anti-HSV-2 Glycoprotein G-2 Monoclonal Antibody, Unconjugated, Clone H1206 from Meridian Life Science, Inc.
...Region By immunoblotting the antibody reacts again...free MMP-2 or MMP-2 bound to TIMP-2. affinity isol... Solution in 0.01 M phosphate buffered saline, pH ...e. synthetic peptide corresponding to the hinge re...
Biology Products: